Congress bans cosmetics animal testing, but FDA keeps emergency override power.

What it does

This bill prohibits cosmetic companies from conducting or contracting for animal testing in the U.S. starting one year after enactment, and bans the sale of cosmetics developed using animal testing. It also blocks the FDA from relying on new animal-test data to prove cosmetic safety unless no non-animal alternative exists and specific exemptions apply (foreign regulatory compliance, FDA-authorized testing for safety concerns, drug-cosmetic hybrids, or non-cosmetic regulatory testing). The bill preempts state cosmetics animal-testing laws, requiring them to match the federal standard.

Why we flagged it

The bill's operative mechanism is a prohibition on animal testing for cosmetics with narrow, safety-justified exemptions. It is fundamentally a consumer-protection and animal-welfare measure, not a deregulation or industry carve-out.

What the text implies

• The preemption clause (State authority section) eliminates state-level cosmetics animal-testing bans, centralizing authority in the FDA. States cannot impose stricter standards, even if constituents demand them—a federalism trade-off that may reduce local democratic input on animal welfare.
• The exemption for 'non-cosmetic purposes' (subsection 4) may allow animal testing on ingredients that are cosmetics-adjacent (e.g., sunscreen actives regulated as drugs) to proceed under different regulatory regimes, creating a potential loophole if companies reclassify products.
• The 60-day public-comment period for FDA-authorized testing is advisory only; the FDA retains final discretion to proceed regardless of public opposition, limiting transparency in individual testing decisions.
• Manufacturers bear the cost of producing and submitting records to the FDA on demand, potentially creating compliance burdens for smaller companies without dedicated regulatory staff.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary consumers gain stronger animal-welfare protections and access to cosmetics developed without animal testing, while facing no direct cost or reduced product choice (alternatives exist and are already widely used). The bill's exemptions preserve FDA authority to require testing only when genuinely necessary for public safety, preventing a blanket ban that could compromise cosmetic safety oversight.

Who stands to gain

• cosmetics manufacturers using or developing non-animal testing methods
• alternative testing technology providers (in vitro, computational modeling firms)
• cruelty-free cosmetics brands

Named in the bill

FDA, HHS Secretary, Interagency Coordinating Committee on the Validation of Alternative Methods, OECD, cosmetics manufacturers, Federal Food, Drug, and Cosmetic Act

Where it stands

158 cosponsors: 145 Democrats, 13 Republicans.

• Feb 27, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 27, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

4 lobbying clients named this bill on 5 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $502,169 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 72% of bills with at least one filing.

Donald Beyer, the sponsor, reported $633,099 in PAC receipts in the 2026 cycle.

• Alticor Inc — $310,000 on 2 filings
• Personal Care Products Council — $140,000 on 1 filing
• Physicians Committee for Responsible Medicine — $42,169 on 1 filing
• Cruelty Free International — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.